Date: 2011-04-26

Type of information: Licensing agreement

Compound: high-throughput screening (HTS) single-cell antibody discovery technology

Company: Vivalis (France) SC World (Japan) Toyama Prefecture (Japan)

Therapeutic area:

Type agreement:


Action mechanism:



Vivalis and SC World have announced the acquisition by Vivalis of SC World’s high-throughput screening (HTS) single-cell antibody discovery technology. The assets transferred include intellectual property (including various patents co-owned withToyama Prefecture), know-how, and physical assets enabling Vivalis to utilize the HTS single-cell technology for human monoclonal antibody discovery. Concurrent with the agreement with SC World, Vivalis has obtained an exclusive license agreement with the Toyama Prefecture, co-owner of certain single cell technology patents, thereby granting to Vivalis an exclusive world-wide license to these patents.
To further improve the HTS single cell technology and expand its commercial activities in Japan and throughout Asia, Vivalis will establish a fully owned subsidiary, Vivalis Toyama Japan, in Toyama. The company will begin operations on May 2nd, 2011, with a team of seven, including one
person in charge of the business development for Asian markets. Four researchers from SC WORLD will join the laboratory located on the campus of Toyama University and Vivalis intends to collaborate with research teams at Toyama University to pursue the development of the single-cell technology acquired from SC WORLD.
With this new acquisition, Vivalis will further strengthen its unique fully integrated offering, from antibody discovery to clinical development.

Financial terms:

Financial terms include up front, milestones and earn out based on revenues.

Latest news:

Is general: Yes